Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

Cited by (380)

Items 101–200 of 380

1. RNA-binding proteins as therapeutic targets in cancer
   Jennifer Jungfleisch, Fátima Gebauer · 2025 · RNA Biology
2. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape
   Prajwal Chaitanya Boddu, Abhishek Kumar Gupta, Rahul Roy, Bárbara de la Peña Avalos, Anne Olazabal‐Herrero, Nils Neuenkirchen, Joshua T. Zimmer, Namrata S. Chandhok, Darren Patrick King, Yasuhito Nannya et al. · 2024 · Molecular Cell
3. Regulatory Potential of the RNA Processing Machinery: Implications for Human Disease
   Kirstyn T. Carey, Vihandha O. Wickramasinghe · 2018 · Trends in Genetics
4. An important class of intron retention events in human erythroblasts is regulated by cryptic exons proposed to function as splicing decoys
   Marilyn Parra, Ben W. Booth, Richard Weiszmann, Brian A. Yee, Gene Wei-Ming Yeo, James Brown, S Celniker, John G. Conboy · 2018 · RNA
5. A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex
   Rakesh Chatrikhi, Callen F. Feeney, Mary J. Pulvino, Georgios Alachouzos, Andrew J. MacRae, Zackary Falls, Sumit Rai, William W. Brennessel, Jermaine L. Jenkins, Matthew J. Walter et al. · 2021 · Cell chemical biology
6. Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
   Yan Jiang, Jean‐Richard Eveillard, Marie‐Anne Couturier, Benoît Soubise, Jian‐Min Chen, Sujun Gao, Audrey Basinko, Fréderic Morel, Nathalie Douet‐Guilbert, Marie‐Bérengère Troadec · 2021 · Cancers
7. Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer
   Koji Kitamura, Keisuke Nimura · 2021 · Cells
8. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
   Saiki, Yuriko, Jiang, Can, Ohmuraya, Masaki, Furukawa, Toru · 2021 · Cancers
9. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins
   Akihide Yoshimi, Omar Ibrahim Abdel-Wahab · 2016 · Clinical Cancer Research
10. Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation
    Nour J. Abdulhay, Claudia Fiorini, Jeffrey M. Verboon, Leif S. Ludwig, Jacob C. Ulirsch, Barbara Zieger, Caleb A. Lareau, Xiaoli Mi, Anindita Roy, Esther A. Obeng et al. · 2019 · The Journal of Experimental Medicine
11. R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
    Zhiyan Silvia Liu, Sayantani Sinha, Maxwell Henry Bannister, Axia Song, Erica A. Arriaga-Gomez, Alexander J. McKeeken, Elizabeth A. Bonner, Benjamin K. Hanson, Martina Sarchi, Kouhei Takashima et al. · 2023 · Cancer Research
12. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations
    Johanna Flach, Johann-Christoph Jann, Antje Knaflic, Vladimir Riabov, Alexander Streuer, Eva Altrock, Qingyu Xu, Nanni Schmitt, Julia Obländer, Verena Nowak et al. · 2020 · Haematologica
13. A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
    Ana Guijarro-Hernández, J.L. Vizmanos · 2021 · Cancers
14. m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis
    Maciej Cieśla, Phuong Cao Thi Ngoc, Sowndarya Muthukumar, Gabriele Todisco, Magdalena Madej, H Fritz, Marios Dimitriou, Danny Incarnato, Eva Hellström‐Lindberg, Cristian Bellodi · 2023 · Molecular Cell
15. BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state
    Muran Xiao, Shinji Kondo, Masaki Nomura, Shinichiro Kato, Koutarou Nishimura, Weijia Zang, Yifan Zhang, Tomohiro Akashi, Aaron D. Viny, Tsukasa Shigehiro et al. · 2023 · Nature Communications
16. We skip to work: alternative splicing in normal and malignant myelopoiesis
    Alex C. H. Wong, John E.J. Rasko, Justin J. -L. Wong · 2018 · Leukemia
17. Regulation of Pre-mRNA Splicing: Indispensable Role of Post-Translational Modifications of Splicing Factors
    Miroslava Kretová, Tomas Selicky, Ingrid Čipáková, Luboš Čipák · 2023 · Life
18. Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine
    Mohammad Alinoor Rahman, Farhana Nasrin, Sonali Bhattacharjee, Saikat Nandi · 2020 · Cancers
19. Aberrant RNA splicing and therapeutic opportunities in cancers
    Hirofumi Yamauchi, Kazuki Nishimura, Akihide Yoshimi · 2021 · Cancer Science
20. Genome-guided discovery of cancer therapeutic targets
    Prathyusha Konda, Simon Garinet, Eliezer M. Van Allen, Srinivas Raghavan Viswanathan · 2023 · Cell Reports
21. How do messenger RNA splicing alterations drive myelodysplasia?
    Poorval M. Joshi, Stephanie Halene, Omar Ibrahim Abdel-Wahab · 2017 · Blood
22. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1
    Shuiling Jin, Hairui Su, Ngoc Tung Tran, Jing Song, Sydney X. Lu, Ying Li, Suming Huang, Omar Ibrahim Abdel-Wahab, Yanyan Liu, Xinyang Zhao · 2017 · PLoS ONE
23. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
    Michael Bauer, Cody Ashby, Christopher P. Wardell, Eileen Mary Boyle, María Ortiz, Erin Flynt, Anjan Thakurta, Gareth John Morgan, Brian A. Walker · 2020 · Haematologica
24. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
    Rashmi Kanagal‐Shamanna, Guillermo Montalban Bravo, Koji Sasaki, Elias Jabbour, Carlos Bueso-Ramos, Yue Wei, Kelly Chien, Tapan Kadia, Farhad Ravandi, Gautam Borthakur et al. · 2021 · Cancer
25. Regulation of erythropoiesis: emerging concepts and therapeutic implications
    Pu Tang, Huaquan Wang · 2023 · Hematology
26. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
    Marcus Bauer, Christoforos Vaxevanis, Nadine Heimer, Haifa Kathrin Al‐Ali, Nadja Jaekel, Michael Philipp Bachmann, Claudia Wickenhauser, Barbara Seliger · 2020 · International Journal of Molecular Sciences
27. Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities
    Daichi Inoue, Omar Ibrahim Abdel-Wahab · 2016 · Cancer Cell
28. Alternative RNA splicing in tumour heterogeneity, plasticity and therapy
    Sebastian Pohl, Kevin Myant · 2022 · Disease Models & Mechanisms
29. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis
    Kanak Joshi, Lei Zhang, Peter Breslin, Ameet R. Kini, Jiwang Zhang · 2022 · Journal of Experimental & Clinical Cancer Research
30. METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
    Yiming Wu, Meiling Jin, Mike Minh Fernandez, Kevyn L. Hart, Aijun Liao, Xinzhou Ge, Stacey M. Fernandes, Tinisha McDonald, Zhenhua Chen, Daniel Röth et al. · 2023 · Blood Cancer Discovery
31. Mutations, inflammation and phenotype of myeloproliferative neoplasms
    Sylvie Hermouet · 2023 · Frontiers in Oncology
32. Splicing factor mutant myelodysplastic syndromes: Recent advances
    Andrea Pellagatti, Jacqueline Boultwood · 2019 · Advances in Biological Regulation
33. PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer
    Long Qian, Xin An, Miao Chen, Nan Wang, Silei Sui, Yixin Li, Changlin Zhang, Kaping Lee, Xiaonan Wang, Tian Tian et al. · 2020 · Frontiers in Oncology
34. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
    Michael K.C. Lee, Sean Michael Grimmond, Grant A. McArthur, Karen E. Sheppard · 2021 · Cancers
35. Somatic Mutations in Core Spliceosome Components Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human Cancer
    Claudio Sette, Maria Paola Paronetto · 2022 · Cancers
36. Therapeutic Targeting of RNA Splicing in Cancer
    Elizabeth A. Bonner, Stanley Chun-Wei Lee · 2023 · Genes
37. Targeting splicing factors for cancer therapy
    Ariel Bashari, Zahava Siegfried, Rotem Karni · 2023 · RNA
38. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process
    Moqin Jiang, Meng Chen, Qian Liu, Zhiling Jin, Xiangdong Yang, Weifeng Zhang · 2023 · Frontiers in Oncology
39. SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation
    Martina Cusan, Haifeng Shen, Bo Zhang, Aijun Liao, Lu Yang, Meiling Jin, Mike Minh Fernandez, Prajish Sundaram Iyer, Yiming Wu, Kevyn L. Hart et al. · 2023 · Journal of Clinical Investigation
40. Protein arginine methyltransferase 1, a major regulator of biological processes
    Sadhana R. N. Sudhakar, Shahper N. Khan, Ariel M. Clark, Thordur Hendrickson-Rebizant, Shrinal Patel, Ted M. Lakowski, James Davie · 2023 · Biochemistry and Cell Biology
41. The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGFβ signaling in zebrafish
    Adriana De La Garza, Rosannah C. Cameron, Varun Gupta, Ellen Fraint, Sara Nik, Teresa Venezia Bowman · 2019 · Blood Advances
42. The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations
    Pushkar Malakar, Sudhanshu Kumar Shukla, Meghna Mondal, Rajesh Kumar Kar, Jawed Akhtar Siddiqui · 2023 · RNA Biology
43. PROTACs in gastrointestinal cancers
    Yu Chen, Qingfan Yang, Jinrun Xu, Liyao Tang, Yan Zhang, Fukuan Du, Yueshui Zhao, Xu Wu, Mingxing Li, Jing Shen et al. · 2022 · Molecular Therapy — Oncolytics
44. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
    Richard Neil Armstrong, Violetta Steeples, Shalini Singh, Andrea Sanchi, Jacqueline Boultwood, Andrea Pellagatti · 2017 · Advances in Biological Regulation
45. Causes and Pathophysiology of Acquired Sideroblastic Anemia
    Juan José Rodríguez‐Sevilla, Xavier Calvo, Leonor Arenillas · 2022 · Genes
46. Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
    Shinsuke Araki, Momoko Ohori, Masato Yugami · 2023 · Frontiers in Oncology
47. The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis
    Ashwin Kishtagari, Ross L. Levine · 2020 · Cold Spring Harbor Perspectives in Medicine
48. Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences
    So Masaki, Shun Ikeda, Asuka Hata, Yusuke Shiozawa, Ayana Kon, Seishi Ogawa, Kenji Suzuki, Fumihiko Hakuno, Shin‐Ichiro Takahashi, Naoyuki Kataoka · 2019 · Frontiers in Genetics
49. SF3B1 Mutations in Hematological Malignancies
    Daniela Cilloni, Federico Itri, Valentina Bonuomo, Jessica Petiti · 2022 · Cancers
50. Dyserythropoiesis of myelodysplastic syndromes
    Carine Lefèvre, Sabrina Bondu, Salomé Le Goff, Olivier Kosmider, Michaëla Fontenay · 2017 · Current Opinion in Hematology
51. Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia
    Karin D. Prummel, Kevin Woods, Maksim M. Kholmatov, Eric C. Schmitt, Evi P. Vlachou, Mayssa Labyadh, Rebekka Wehner, Gereon Poschmann, Kai Stühler, Susann Winter et al. · 2025 · Nature Communications
52. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome
    Mizuho Shirahata‐Adachi, Chisako Iriyama, Akihiro Tomita, Yasuhíro Suzuki, Kazuyuki Shimada, Hitoshi Kiyoi · 2017 · Leukemia Research
53. A Comprehensive Overview of Structure‐Activity Relationships of Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents
    Datong Zhang, Fancui Meng · 2020 · ChemMedChem
54. Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
    Laura Palomo, Pamela Acha, Francesc Gessé Solé · 2021 · Cancers
55. Myelodysplastic syndrome patient-derived xenografts: from no options to many
    Christophé Côme, Alexander Balhuizen, Dominique A. Bonnet, Bo Torben Porse · 2020 · Haematologica
56. Antisense oligonucleotide-mediated TRA2β poison exon inclusion induces the expression of a lncRNA with anti-tumor effects
    Nathan K. Leclair, Mattia Brugiolo, SungHee Park, Maëva Devoucoux, Laura M. Urbanski, Brittany Lynn Angarola, Marina Yurieva, Olga Anczuków · 2025 · Nature Communications
57. Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin
    Tushar Murthy, Theresa Bluemn, Abhishek Kumar Gupta, Michael H. Reimer, Sridhar Rao, Manoj M. Pillai, Alex C. Minella · 2018 · Journal of Biological Chemistry
58. Conditional switching of KIF2A mutation provides new insights into cortical malformation pathogeny
    Johan Gilet, Ekaterina L. Ivanova, Daria Trofimova, Gabrielle Rudolf, Hamid Méziane, Loïc Broix, Nathalie Drouot, Jérémie Courraud, Valerie Skory, Paul Voulleminot et al. · 2019 · Human Molecular Genetics
59. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
    Atsushi Tanaka, Taizo A. Nakano, Masaki Nomura, Hiromi Yamazaki, Jan Philipp Bewersdorf, Roger Mulet‐Lazaro, Simon J. Hogg, Bo Liu, Alex Penson, Akihiko Yokoyama et al. · 2022 · Blood
60. Post-transcriptional regulation in hematopoiesis: RNA binding proteins take control
    Laura P. M. H. de Rooij, Derek C.H. Chan, Ava Keyvani Chahi, Kristin J. Hope · 2018 · Biochemistry and Cell Biology
61. Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis
    Satish Kumar Nandakumar, Sean McFarland, Laura Marlene Mateyka, Caleb A. Lareau, Jacob C. Ulirsch, Leif S. Ludwig, Gaurav Agarwal, J Engreitz, Bartlomiej P. Przychodzen, Marie Ellen McConkey et al. · 2019 · eLife
62. A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
    Edda María Elvarsdóttir, Teresa Mortera Blanco, Marios Dimitriou, Thibault Bouderlique, Monika Jansson, Isabel Juliana Hofman, Simona Conte, Mohsen Karimi, Birgitta Sander, Iyadh Douagi et al. · 2019 · Leukemia
63. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
    Justin Taylor, Xiaoli Mi, Alexander V. Penson, Stella V. Paffenholz, Kelsey Alvarez, Allison M. Sigler, Stephen S. Chung, Raajit K. Rampal, Jae H. Park, Eytan M. Stein et al. · 2020 · The Lancet Haematology
64. SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
    Irene López‐Oreja, André Gohr, Heribert Playà-Albinyana, Ariadna Giró, Fabián Arenas, Morihiro Higashi, Rupal Tripathi, Mònica López‐Guerra, Manuel Irimia, Marta Aymerich et al. · 2023 · Life Science Alliance
65. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
    Vikas Madan, Jia Li, Siqin Zhou, Weoi Woon Teoh, Lin Han, Manja Meggendorfer, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Torsten Haferlach et al. · 2019 · American Journal of Hematology
66. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
    Juan José Rodríguez‐Sevilla, Vera Ademà, Guillermo Garcia‐Manero, Simona Colla · 2023 · Cell Reports Medicine
67. Age-Related Alternative Splicing: Driver or Passenger in the Aging Process?
    Marco Baralle, Maurizio Romano · 2023 · Cells
68. Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
    Marie Hautin, Clélia Mornet, Aurélie Chauveau, Delphine G. Bernard, Laurent Corcos, Éric Lippert · 2020 · Cancers
69. A splicing factor switch controls hematopoietic lineage specification of pluripotent stem cells
    Yapu Li, Ding Wang, Hongtao Wang, Xin Huang, Yuqi Wen, Bingrui Wang, Zefeng Xu, Jie Gao, Jinhua Liu, Jingyuan Tong et al. · 2020 · EMBO Reports
70. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice
    Sanghyun Peter Kim, Sridhar Nonavinkere Srivatsan, Monique Chavez, Cara Lunn Shirai, Brian S. White, Tanzir Ahmed, Michael O. Alberti, Jin Shao, Ryan M. Nunley, Lynn S. White et al. · 2021 · Cell Reports
71. Splicing modulators elicit global translational repression by condensate-prone proteins translated from introns
    Jagat K Chhipi-Shrestha, Tilman Schneider‐Poetsch, Takehiro Suzuki, Mari Mito, Khalid Khan, Naoshi Dohmae, Shintaro Iwasaki, Minoru Yoshida · 2021 · Cell chemical biology
72. Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells
    Sanjay Mukherjee, Abdullah Mahmood Ali, Vundavalli V.V.S. Murty, Azra Raza · 2022 · Medical Oncology
73. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
    Christina‐Nefeli Kontandreopoulou, Konstantinos Kalopisis, Nora‐Athina Viniou, Panagiotis Theodorou Diamantopoulos · 2022 · Frontiers in Oncology
74. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
    Tamanna Zohra Haque, Félix López Cadenas, Blanca Xicoy, Ana Alfonso Piérola, Uwe Platzbecker, Irit Mazza Avivi, Andrew Mark Brunner, Jöerg Chromik, Daniel Morillo, Manish R. Patel et al. · 2023 · Leukemia Research
75. Citrullination and the protein code: crosstalk between post-translational modifications in cancer
    Koyo Harada, Simon Mark Carr, Amit Shrestha, Nicholas Barrie La Thangue · 2023 · Philosophical Transactions of the Royal Society B Biological Sciences
76. RNA splicing during terminal erythropoiesis
    John G. Conboy · 2017 · Current Opinion in Hematology
77. An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications
    Yihui H. Shi, Walter M. Bray, Alexander J. Smith, Wei Zhou, Joy M. Calaoagan, Chandraiah Lagisetti, Lidia C. Sambucetti, Phillip Crews, R. Scott Lokey, Thomas R. Webb · 2020 · PLoS ONE
78. SF3B1 mutant myelodysplastic syndrome: Recent advances
    Andrea Pellagatti, Jacqueline Boultwood · 2020 · Advances in Biological Regulation
79. U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice
    Brian A. Wadugu, Sridhar Nonavinkere Srivatsan, Amanda D. Heard, Michael O. Alberti, Matthew Ndonwi, Jie Liu, Sarah Grieb, Joseph L. Bradley, Jin Shao, Tanzir Ahmed et al. · 2021 · Journal of Clinical Investigation
80. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T
    Akihide Yoshimi, Omar Ibrahim Abdel-Wahab · 2017 · International Journal of Hematology
81. Smc3 is required for mouse embryonic and adult hematopoiesis
    Tianjiao Wang, Brandi K. Glover, Gayla Hadwiger, Christopher A. Miller, Orsola di Martino, John Sutton Welch · 2018 · Experimental Hematology
82. ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells
    Vikas Madan, Zeya Cao, Weoi Woon Teoh, Pushkar Dakle, Lin Han, Pavithra Shyamsunder, Maya Jeitany, Siqin Zhou, Jia Li, Hazimah Binte Mohd Nordin et al. · 2021 · Haematologica
83. Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
    Camilla Bertuzzo Veiga, Erin Lawrence, Andrew James Murphy, Marco J. Herold, Dragana Dragoljevic · 2021 · Cancers
84. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response
    Aaron Y. Chang, Yu Zhou, Sharanya Iyengar, Piotr W. Pobiarzyn, Pavel Tishchenko, Kesha M. Shah, Heather Wheeler, Yueming Wang, Paula M. Loria, Frank Loganzo et al. · 2021 · Journal of Biological Chemistry
85. The Coming of Age of Preclinical Models of MDS
    Wei Liu, Patric Teodorescu, Stephanie Halene, Gabriel Ghiaur · 2022 · Frontiers in Oncology
86. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment
    Andrea Pellagatti, Jacqueline Boultwood · 2022 · Advances in Biological Regulation
87. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
    Georgios Asimomitis, André G. Deslauriers, Andriana G. Kotini, Elsa Bernard, Davide Esposito, Malgorzata Olszewska, Nikolaos Spyrou, Juan Arango Ossa, Teresa Mortera Blanco, Richard P. Koche et al. · 2022 · Blood Advances
88. The SF3b Complex is an Integral Component of the Spliceosome and Targeted by Natural Product-Based Inhibitors
    Nicholas Larsen · 2020 · Sub-cellular biochemistry/Subcellular biochemistry
89. A UHM–ULM interface with unusual structural features contributes to U2AF2 and SF3B1 association for pre-mRNA splicing
    Justin W. Galardi, Victoria N. Bela, Nazish N. Jeffery, Xueyang He, Eliezra Glasser, Sarah Loerch, Jermaine L. Jenkins, Mary J. Pulvino, Paul L. Boutz, Clara L. Kielkopf · 2022 · Journal of Biological Chemistry
90. Mechanisms underlying the heterogeneity of myelodysplastic syndromes
    Charles Dussiau, Michaëla Fontenay · 2017 · Experimental Hematology
91. Therapeutic approaches to treat human spliceosomal diseases
    Anthony B. DeNicola, Yi Tang · 2019 · Current Opinion in Biotechnology
92. Modeling Myeloid Malignancies Using Zebrafish
    Kathryn S. Potts, Teresa Venezia Bowman · 2017 · Frontiers in Oncology
93. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing
    Xènia Serrat, Dmytro Kukhtar, Eric Cornes, Anna Esteve‐Codina, Helena Benlloch, Germano Cecere, Julián Cerón · 2019 · PLoS Genetics
94. Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of SF3B1 mutations
    Alicja Pacholewska, Matthias Lienhard, Mirko Brüggemann, Heike Hänel, Lorina Bilalli, Anja Königs, Felix Heß, Kerstin Becker, Karl Köhrer, Jesko Kaiser et al. · 2024 · Genome Research
95. Dysregulated minor intron splicing in cancer
    Koutarou Nishimura, Hiromi Yamazaki, Weijia Zang, Daichi Inoue · 2022 · Cancer Science
96. SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer
    Patrik Simmler, Cédric Cortijo, Lisa Maria Koch, Patricia Galliker, Silvia Angori, Hella Anna Bolck, Christina Mueller, Ana Vukolic, Peter Mirtschink, Yann Christinat et al. · 2022 · Cell Reports
97. Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients
    Timothy I. Shaw, Bi Zhao, Yuxin Li, Hong Wang, Liang Wang, Brandon J. Manley, Paul A. Stewart, Aleksandra M. Karolak · 2022 · Frontiers in Oncology
98. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations
    Xiao‐lian Liu, Zhou Run‐hua, Jingxuan Pan, Zhijie Li, Le Yu, Yilei Li · 2024 · Pigment Cell & Melanoma Research
99. Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition
    Martina Sarchi, Courtnee A. Clough, Edie I. Crosse, Jason Kim, Laura D. Baquero Galvis, Nelli Aydinyan, Rachel Wellington, Feini Yang, Anna Gallì, John Philip Creamer et al. · 2024 · Blood Cancer Discovery
100. Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations
     Joseph Pangallo, Jean‐Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob Tyler Polaski, Khrystyna North, Omar Ibrahim Abdel-Wahab, Robert K. Bradley · 2020 · Blood